Group 1: Financial Performance - In 2022, the company achieved a revenue of 208,425.04 million CNY, representing a year-on-year growth of 3.84% [3] - The net profit attributable to the parent company was 34,669.87 million CNY, a decrease of 16.01% compared to the previous year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 28,071.54 million CNY, down by 1.37% year-on-year [3] Group 2: Production and Capacity Expansion - The company completed several capacity expansion projects, including the "New GMP Upgrade and Expansion Project" and "Natural Plant Industry Base," significantly increasing production capacity [3] - The new raw material drug factory of Longxiang Pharmaceutical began trial production in March 2022, with full capacity expected to be released in 2023 [6] Group 3: Research and Development - In 2022, the company obtained 8 new veterinary drug registration certificates and 35 patent technologies, achieving a record high in new veterinary drug registrations [3] - R&D investment increased by 11% in 2022, focusing on high-end talent recruitment and the "independent R&D + joint tackling" model [6] Group 4: Market Strategy and Product Development - The company plans to launch several new products in 2023, including vaccines for pigs and pets, enhancing its product matrix [7] - The pet segment revenue doubled in 2022, with a focus on expanding strategic cooperation with major clients in 2023 [4] Group 5: Strategic Partnerships - The company announced a strategic partnership with Shengnong Development and Shengwei Biological, aiming to enhance R&D capabilities and expand sales channels [5] - The collaboration will establish a poultry disease prevention research institute and a disease monitoring and early warning platform [5]

Financial Performance - The company reported a profit distribution plan to distribute a cash dividend of 3 RMB per 10 shares (including tax) based on a total of 468,018,786 shares[4]. - The company's operating revenue for 2022 was CNY 2,084,250,399, representing a 3.84% increase compared to CNY 2,007,138,304.57 in 2021[23]. - The net profit attributable to shareholders decreased by 16.01% to CNY 346,698,684.97 in 2022 from CNY 412,784,534.66 in 2021[23]. - The basic earnings per share fell by 27.00% to CNY 0.7488 in 2022, down from CNY 1.0258 in 2021[23]. - The total assets increased by 7.30% to CNY 6,106,273,672.25 at the end of 2022, compared to CNY 5,690,781,226.40 at the end of 2021[23]. - The net cash flow from operating activities was CNY 389,486,980.07, a 1.79% increase from CNY 382,628,909.13 in 2021[23]. - The company achieved a revenue of CNY 2,084.25 million in 2022, representing a year-on-year growth of 3.84%[71]. - The net profit attributable to the parent company was CNY 346.70 million, a decrease of 16.01% compared to the previous year[71]. - The total revenue for 2022 was CNY 2,084,250,399, representing a 3.84% increase from CNY 2,007,138,304.57 in 2021[89]. Market Position and Strategy - The company operates in the animal health sector, focusing on veterinary drugs and biological products for disease prevention and treatment[17]. - The company is positioned in the veterinary medicine manufacturing industry, providing disease prevention products and services for economic and companion animals[34]. - The company is recognized as one of the largest veterinary drug enterprises in China, with the most comprehensive product range and a focus on animal disease prevention solutions[40]. - The company has established strategic partnerships with top 300 poultry and top 200 livestock farming groups, enhancing market coverage and sales proportion[47]. - The company aims to cover 1,500 key poultry farming counties and 1,000 key livestock farming counties in China, focusing on small and medium-sized farms[49]. - The company has introduced a new pet product line, including dewormers and ear medications, and is strengthening its sales channels through strategic partnerships[50]. - The company has established multiple national and provincial innovation platforms, enhancing its research capabilities and fostering collaboration with over 30 renowned research institutions[61]. - The company is actively seeking overseas investment opportunities to implement its "going out" strategy and gradually expand its international market presence[149]. Research and Development - The company has developed 494 veterinary drug products, including 116 biological products and 198 chemical drug formulations, making it one of the largest enterprises in the domestic veterinary drug industry[65]. - The company has a strong focus on innovation, with 14 core technology platforms for drug research and development, including an AI drug development platform[71]. - The company has received 20 invention patents and 15 utility model patents during the reporting period, totaling 172 invention patents and 67 utility model patents by the end of the reporting period[74]. - The company achieved a research and development investment of ¥168,372,422.90 in 2022, representing an increase of 11.06% from ¥151,631,979.07 in 2021[106]. - The R&D investment accounted for 8.08% of the total operating revenue in 2022, up from 7.55% in 2021[106]. - The company has a total of 324 R&D personnel, including 20 PhDs and 199 master's degree holders, enhancing its research capabilities[75]. - The company has made significant breakthroughs in new product development, particularly in the fields of genetic engineering vaccines and multi-valent vaccines[71]. - The company is focusing on innovation and increasing R&D investment, which is expected to enhance its overall competitiveness in the industry[102]. Risks and Challenges - The company faces risks including animal epidemic risks, market competition risks, talent loss risks, and product development risks[4]. - The competitive landscape in the veterinary medicine industry is intensifying, prompting the company to optimize its industrial layout and enhance its comprehensive strength[151]. - The R&D cycle for veterinary products is long and uncertain, with risks associated with obtaining necessary approvals and market conditions[154]. - The company has implemented a strict credit management policy to mitigate risks associated with high accounts receivable, ensuring most customer debts remain within normal credit periods[156]. Governance and Management - The company emphasizes the importance of accurate financial reporting and has a dedicated team for financial oversight[4]. - The company has a clear ownership structure, with all intangible and tangible assets owned independently, ensuring no asset occupation by the controlling shareholder[175]. - The company has taken effective measures to protect the rights of minority shareholders during significant decision-making processes[162]. - The board of directors consists of 9 members, including 3 independent directors, enhancing decision-making capabilities and governance standards[164]. - The company has implemented a performance evaluation and incentive system for directors and senior management, promoting long-term development[171]. - The company has actively improved investor relations management, ensuring timely and accurate information disclosure to all shareholders[170]. - The company has established a dedicated investor hotline and email to address investor inquiries, enhancing communication transparency[170]. Future Outlook - The company’s future outlook includes potential market expansion and new product development in the veterinary sector[4]. - In 2023, the company plans to launch new products in the livestock sector, including inactivated vaccines for pig reproductive and respiratory syndrome and porcine circovirus, which will enhance product competitiveness[55]. - The poultry sector will introduce new products such as the LaSota+LDT3 bivalent live vaccine and inactivated vaccines, aiming to improve disease prevention solutions and expand channel coverage[55]. - The company plans to launch multiple new vaccines in 2023, including a trivalent inactivated vaccine for avian influenza and a gene-engineered vaccine for porcine circovirus type 2, contributing to high-quality development[142]. - The company is focusing on digital transformation, aiming to establish a digital manufacturing platform for veterinary drugs, integrating AI, information technology, and automation[146].

证券代码：300119 证券简称：瑞普生物 公告编号：2023-022 天津瑞普生物技术股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）《2022年年度报告》 全文及摘要以及其他相关文件已于2023年4月1日刊登在中国证券监督管理委员 会指定的创业板信息披露网站。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二三年四月一日 1 为便于广大投资者进一步了解公司2022年年度报告及经营情况，公司拟定于 2023年4月14日（星期五）下午15:00-17:00在"价值在线（www.ir-online.cn）" 举行2022年度业绩说明会。本次年度业绩说明会将采用网络远程的方式举行，投 资者可登录"价值在线（www.ir-online.cn）"参与本次说明会。 公司董事长李守军先生，独立董事周睿女士，财务负责人李改变女士，保 荐代表人郭玉良女士，董事会秘书谢刚先生将出席本次说明会。 为充分尊重投资者，提升本次交流的针对性，现就公司2022年度业绩说明 会提 ...

Group 1: Industry Challenges - The poultry market has faced unprecedented difficulties due to H7N9 avian flu and food safety incidents, leading to a prolonged downturn in chicken consumption [2] - The pig farming sector experienced continuous losses throughout the year, with significant losses at the beginning of the year [3] - The animal health industry has seen a slow recovery in market conditions, resulting in a decline in company performance [3] Group 2: Organizational Adjustments - The company is implementing a "research-production-sales integration" strategy, establishing various development centers to respond to market changes and enhance industry development [3] - A new group control model focusing on "industry development centers," "profit centers," and "responsibility centers" is being adopted to improve organizational efficiency and core competitiveness [3] Group 3: Product Development - The company is developing a range of new livestock products, including vaccines for porcine infectious gastroenteritis and porcine epidemic diarrhea [3] - The animal vaccine expansion project is currently underway, with plans to launch several new products in 2015 [3]

证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：15 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 安信证券 郑颖欣、博时基金 葛晨、中银基金 王帅、华夏基 | | | | | | 人员姓名 | | 金 李恒、招商证券 周莎、国投瑞银 孙文龙、鹏山资产 杨明 | | | 石岩。 | 韬、平安资管 黄文峰、浙银金阁 朱学根、和君咨询 乔圣泽 | | 时间 | 2016 年 9 月 22 | 日 10:30-12:00 | | 地点 | 公司九楼会议室 | | | 上市公司接待人 | | 董事长、总经理 李守军 副 ...

Group 1: Company Development and Strategy - The company has transformed from a product seller to a comprehensive service provider, learning from leading global animal health companies [1] - In Q1 2020, the company achieved rapid growth due to strategic planning over the past few years [1] - The company has made significant progress in internal management efficiency and product development, focusing on future-oriented planning [3] Group 2: Vaccine Development and Market Position - The company emphasizes dual improvements in technical and product standards for poultry vaccines, achieving a replacement of imported products with stable quality [3] - Plans to establish a research center for avian influenza vaccines in Southern China, enhancing production capacity and targeting ASEAN markets [3] - The poultry business is well-structured and maintains high-speed, healthy growth [3] Group 3: Innovations in Livestock Products - The company has innovated marketing models in livestock vaccines, focusing on customer-centric approaches and service provision [3] - A mature mechanism for product sales has been established, with plans for large-scale promotion [3] - Internal departments are aligned under a customer-centric principle, contributing to overall value [3] Group 4: Core Competitiveness in Animal Health Industry - Short-term competitiveness relies on marketing capabilities, while mid-term focus is on management and production stability, and long-term on R&D capabilities [3] Group 5: Pet Products Sector - The pet products sector is a strategic focus, with rapid growth in pet pharmaceuticals and vaccines [4] - The company plans to deepen collaboration with its affiliate, Ruipai Pet Hospital, to enhance product promotion [4] Group 6: Future Trends in Animal Health Industry - The animal health industry is expected to accelerate consolidation towards larger and leading companies, providing greater development space for industry leaders [4]

Group 1: Industry Changes and Impact - The African swine fever epidemic has significantly impacted China's livestock industry, leading to a severe reduction in pig farming capacity and increased demand for chicken meat as a substitute [4]. - The market for poultry vaccines has expanded following the upgrade of avian influenza vaccine products at the end of last year, indicating a growing trend towards reduced antibiotic use in the livestock sector [4]. Group 2: Poultry Industry Development - The poultry farming industry is experiencing standardization in the broiler sector and scaling in the egg-laying sector, with the broiler industry showing a higher degree of scalability [4]. - The African swine fever epidemic may affect consumer meat product consumption, with white feather broilers likely to fill the gap in consumption structure, driving rapid development in the poultry farming industry [4]. Group 3: Company Progress in Avian Influenza Vaccine Market - The company’s subsidiary, Guangzhou South China Agricultural University Biological Pharmaceutical Co., Ltd., has received approval for a trivalent inactivated vaccine, which will fully participate in market bidding this year [5]. - The company plans to leverage its long-term quality resources to enhance marketing efforts for avian influenza vaccines and reduce production costs through the use of suspension culture technology [5]. Group 4: Future Development Directions - The successful approval of the trivalent inactivated vaccine (H5+H7) will be a key product for the company over the next three years, with the poultry farming industry's ongoing prosperity expected to drive both volume and price increases for poultry vaccines [5]. - The company aims to expand into the pet vaccine and pet medicine sectors, anticipating significant growth opportunities in these areas over the next 20 years [5].

Group 1: Company Overview - The company introduced its 2020 performance highlights and operational achievements, along with plans for a non-public offering and strategic direction [1] - The focus was on expanding distribution channels and increasing coverage in key domestic breeding counties [4] Group 2: Product and Quality Management - The company established a quality management center and centralized procurement department to oversee quality and material procurement across subsidiaries [4] - A revised quality philosophy and objectives were implemented, with product line management aimed at improving product quality based on customer needs [4] Group 3: Strategic Transformation and Organizational Incentives - The company initiated comprehensive management changes starting with strategic transformation [4] - Organizational restructuring was undertaken to enhance the marketing system and allocate resources towards strategic business areas [4] - An incentive mechanism was established to promote performance and encourage young talent, including job rotation and performance-based elimination [4] Group 4: Pet Hospital Development - The company plans to expand cooperation with Ruipai Pet Hospital and broaden the pet distributor network [4] - Focus on core and specialty products in the pet business segment to provide integrated solutions for customers [4] - Accelerating digital transformation and e-commerce capabilities in the pet sector [4]

编号：2021-002 1 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：电话交流会 | | | 参与单位名称及 | 西南证券：徐卿，刘佳宜 | | | 人员姓名 | 淡水泉：俞仁钦 | | | | 银叶投资：刁凯峰 | | | | 中庚基金：张炜舜 | | | | | | | | | | | | 工银瑞信：王鹏 大成基金：齐炜中 中国农业产业基金：万毅 长安基金：朱施乐 | | | 时间 | 2021 ...

证券代码：300119 证券简称：瑞普生物 编号：2022-001 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | □特定对象调研 □媒体采访 □业绩说明会 □新闻发布会 现场参观 其他（电话会议） | 分析师会议 □路演活动 | | 参与单位名称及 ...